Forte Biosciences Raises Money to Power Autoimmune Breakthroughs
Forte Biosciences, Inc., a clinical-stage biopharmaceutical company specializing in autoimmune and autoimmune-related diseases, announced today the successful close of an oversubscribed equity financing round. Paul Wagner, Ph.D., Chairman and CEO of Forte Biosciences states, "This financing by high quality institutional investors is transformative for Forte and highlights the meaningful potential for FB102. As a result of the financing, Forte is well capitalized to continue advancing FB102 across autoimmune indications"
Forte Biosciences Raises Money to Power Autoimmune Breakthroughs